Skip to main content
Sopharma AD logo

Sopharma AD — Investor Relations & Filings

Ticker · SFA ISIN · BG11SOSOBT18 LEI · 097900BGGW0000048796 BSOBGN Manufacturing
Open in API
Filings indexed 1,482 across all filing types
Latest filing 2023-09-29 Director's Dealing
Country BG Bulgaria
Listing BSOBGN SFA

About Sopharma AD

https://www.sopharmagroup.com/

Sopharma AD is a pharmaceutical company founded in 1933 that specializes in the production, distribution, and export of a wide range of medical products. The company's portfolio includes prescription (Rx) and over-the-counter (OTC) medicines, encompassing both branded and generic drugs. A key area of focus is its traditional plant-based products. Sopharma develops treatments for various conditions, including liver disease, pain management, and smoking cessation. Operating from EU-GMP certified facilities, the company also provides contract manufacturing services and has an established presence in over 40 international markets.

Recent filings

Filing Released Lang Actions
Notification from "Donev investments holding" AD under Art. 19 of Regulation (EU) No 596/2014 of 28 September 2023.
Director's Dealing Classification · 100% confidence The document text clearly details a 'notification' concerning 'Details of the person discharging managerial responsibilities/person closely associated' and includes sections for 'Details of the transaction(s)' specifying 'Nature of the transaction' as 'Sell' and listing 'Price(s) and volume(s)'. This structure is characteristic of mandatory regulatory filings reporting insider transactions, specifically director's dealings or transactions by persons closely associated with management. Comparing this to the provided definitions, 'Director's Dealing (Code: DIRS)' is the most appropriate classification.
2023-09-29 English
Notification from "Donev investments holding" AD under Art. 19 of Regulation (EU) No 596/2014 of 28 September 2023.
Director's Dealing Classification · 100% confidence The document text explicitly details a 'NOTIFICATION OF INSIDERS' TRANSACTIONS under art. 19 of Regulation 596/2014'. It lists the 'Details of the person discharging managerial responsibilities/person closely associated' (Donev Investments Holding AD, related to Sopharma AD) and provides specific transaction details (Nature of transaction: Buy, Price(s) and volume(s), Date of the transaction: 28.9.2023). This content directly corresponds to the reporting requirements for insider trading or director's dealings, which maps to the 'Director's Dealing' category (DIRS).
2023-09-29 English
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of 28 September 2023.
Director's Dealing Classification · 100% confidence The document text details a transaction involving a person discharging managerial responsibilities ('Ognian Donev') concerning financial instruments ('Warrants') of an issuer ('Sopharma AD'). It specifies the nature of the transaction ('Buy'), the price, and the volume. This structure is characteristic of mandatory insider trading disclosures, specifically reporting personal share transactions by company directors and executives. This aligns directly with the definition for Director's Dealing (DIRS).
2023-09-29 English
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of 28 September 2023.
Director's Dealing Classification · 100% confidence The document details a transaction involving a 'person discharging managerial responsibilities' (Ognian Donev, Executive director and chairman of the Board of directors of Sopharma AD) regarding the purchase ('Buy') of company shares. This structure—reporting personal transactions by directors/executives—is characteristic of insider trading disclosures, often mandated by regulations like MAR (Market Abuse Regulation) in the EU. Among the provided codes, 'Director's Dealing' (DIRS) is the most specific match for reporting personal share transactions by company directors and executives.
2023-09-29 English
A transaction concluded by the subsidiary "Pharmalogistika" AD under Art. 114, para. 3 of the LPOS requiring prior approval by the public company
Regulatory Filings Classification · 95% confidence The document is a formal 'NOTIFICATION' from 'Sopharma' AD regarding a transaction concluded by its subsidiary, 'Pharmalogistika' AD, with 'Sopharma Trading' AD. The notification explicitly references specific articles of a law (Art. 114, para. 3 of the LPOS) concerning related-party transactions, disclosure of stakeholder interests, and valuation thresholds. This structure—detailing a specific corporate action (a lease agreement) that involves related parties and requires regulatory disclosure based on its value—is characteristic of mandatory corporate governance or transaction disclosures, often falling under general regulatory announcements or specific transaction reporting requirements. Since there is no specific category for 'Related Party Transaction Disclosure' and it is not an earnings release (ER), management discussion (MDA), or director dealing (DIRS), it best fits the general regulatory filing category, RNS, as it is a mandatory notification of a significant corporate event/transaction under local regulations.
2023-09-29 English
Notification from "Donev investments holding" AD under Art. 19 of Regulation (EU) No 596/2014 of 27 September 2023.
Director's Dealing Classification · 100% confidence The document text explicitly contains the heading "NOTIFICATION OF INSIDERS' TRANSACTIONS under art. 19 of Regulation 596/2014". It details transactions made by a 'person discharging managerial responsibilities' or a 'person closely associated' (Donev Investments Holding AD in relation to Sopharma AD). This structure, focusing on insider trading reports mandated by EU regulations (like MAR 596/2014), directly corresponds to the definition of Director's Dealing reports.
2023-09-28 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.